The David Scheinberg Lab
Projects

David A. Scheinberg, MD, PhD

Member

Share
Print
Share
Print
David A. Scheinberg, MD, PhD

Office Phone

646-888-2190

Office Fax

646-422-0296

Lab Phone

646-888-2205

Lab Fax

646-422-0640

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

  • Actinium
    Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
  • Arvinas, Inc
    Ownership / Equity Interests
  • Bridge Medicines
    Provision of Services (uncompensated)
  • ContraFect
    Ownership / Equity Interests
  • Ensysce Bioscience
    Ownership / Equity Interests
  • Eureka Therapeutics Inc
    Ownership / Equity Interests; Provision of Services (uncompensated)
  • Great Point Partners
    Ownership / Equity Interests; Provision of Services
  • Iovance Biotherapeutics, Inc.
    Ownership / Equity Interests
  • KLUS Pharma, Inc
    Provision of Services
  • Lantheus Medical Imaging, Inc.
    Ownership / Equity Interests
  • OncoPep, Inc.
    Provision of Services
  • Pfizer, Inc.
    Ownership / Equity Interests; Provision of Services
  • Progenics Pharmaceuticals, Inc.
    Provision of Services (uncompensated)
  • Sapience Therapeutics, Inc.
    Fiduciary Role/Position; Ownership / Equity Interests
  • Sellas Life Science Group
    Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures